Dagay Andrew, Katzav Shlomit, Elisha Noa, Volkov Jana, Tauman Riva, Giladi Nir, Hausdorff Jeffrey M, Mirelman Anat, Zitser Jennifer
Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Laboratory for Early Markers of Neurodegeneration (LEMON), Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
NPJ Parkinsons Dis. 2025 Jul 14;11(1):211. doi: 10.1038/s41531-025-01057-1.
Recent work has shown that REM density, defined as the number of rapid eye movements per REM sleep minute, is decreased in people with Parkinson's disease (PD) and is associated with greater bradykinesia, suggesting a motor component. This study explored the association of REM density with gait, cognitive function, and heart rate variability (HRV). Seventy-seven PD patients underwent overnight polysomnography. Gait was evaluated using wearable technology during preferred-speed walking and while walking with a cognitive task (dual tasking). Lower REM density was associated with poorer gait and mobility, particularly during dual-tasking and turning, but not with HRV. Patients taking evening slow-release dopaminergic medication showed higher REM density compared to drug-naïve patients or those on daytime medication. These findings highlight the role of motor and cognitive functions in the generation of rapid eye movements in PD. Administration of evening medications appears to improve REM density, likely by alleviating motor control deficits.
近期研究表明，快速眼动睡眠密度（定义为每快速眼动睡眠分钟的快速眼动次数）在帕金森病（PD）患者中降低，且与更严重的运动迟缓相关，提示存在运动成分。本研究探讨了快速眼动睡眠密度与步态、认知功能和心率变异性（HRV）之间的关联。77例PD患者接受了夜间多导睡眠监测。在以偏好速度行走以及在执行认知任务（双重任务）时行走期间，使用可穿戴技术评估步态。较低的快速眼动睡眠密度与较差的步态和活动能力相关，尤其是在双重任务和转弯时，但与心率变异性无关。与未服用药物的患者或服用日间药物的患者相比，服用晚间缓释多巴胺能药物的患者快速眼动睡眠密度更高。这些发现突出了运动和认知功能在PD患者快速眼动产生中的作用。晚间给药似乎可改善快速眼动睡眠密度，可能是通过减轻运动控制缺陷来实现的。
